Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

Atea Pharmaceuticals (AVIR) announced the poster presentation of bemnifosbuvir preclinical data at the 38th International Conference on ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ...

A successful blood borne virus (BBV) opt-out testing programme is being expanded across NHS Greater Manchester emergency departments (A&E) during March.

Beacon Hill Roll Call records local senator’s votes on roll calls from recent Senate debate on a fiscal 2025 supplemental ...

The Brazilian subsidiary saw a 90% increase in sales compared to the previous year, thanks to government contracts for HIV and hepatitis C diagnosis kits and expanded supply of COVID-19 and dengue ...

New Study Identifies Key Protein's Role in Psoriasis Jan. 31, 2025 — In a new study, researchers have determined that a protein called NF-kB c-Rel can ... against hepatitis B virus was clearly ...

Video Back Videos home Signature collection Essentials collection Artificial Intelligence ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

The hepatitis A virus (HAV) is one of the main causes of viral hepatitis and is responsible for an estimated 159,000 ...